Abstract:IMPORTANCE Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) may have different effects on cardiovascular (CV) events in patients with diabetes mellitus (DM). OBJECTIVE To conduct ameta-analysis to separately evaluate the effects of ACEIs and ARBs on all-cause mortality, CV deaths, and major CV events in patients with DM. DATA SOURCES Data sources included MEDLINE (1966-2012), EMBASE (1988-2012), the Cochrane Central Register of Controlled Trials, conference proceedings, and article reference lists. STUDY SELECTION We included randomized clinical trials reporting the effects of ACEI and ARB regimens for DM on all-cause mortality, CV deaths, and major CV events with an observation period of at least 12 months. Studies were excluded if they were crossover trials. DATA EXTRACTION AND SYNTHESIS Dichotomous outcome data from individual trials were analyzed using the risk ratio (RR) measure and its 95% CI with random-effects models. We estimated the difference between the estimates of the subgroups according to tests for interaction. We performed meta-regression analyses to identify sources of heterogeneity. MAIN OUTCOMES AND MEASURES Primary end points were all-cause mortality and death from CV causes. Secondary end points were the effects of ACEIs and ARBs on major CV events. RESULTS Twenty-three of 35 identified trials compared ACEIs with placebo or active drugs (32 827 patients) and 13 compared ARBs with no therapy (controls) (23 867 patients). When compared with controls (placebo/active treatment), ACEIs significantly reduced the risk of all-cause mortality by 13%(RR, 0.87; 95% CI, 0.78-0.98), CV deaths by 17%(0.83; 0.70-0.99), and major CV events by 14%(0.86; 0.77-0.95), including myocardial infarction by 21% (0.79; 0.65-0.95) and heart failure by 19% (0.81; 0.71-0.93). Treatment with ARBs did not significantly affect all-cause mortality (RR, 0.94; 95% CI, 0.82-1.08), CV death rate (1.21; 0.81-1.80), and major CV events (0.94; 0.85-1.01) with the exception of heart failure (0.70; 0.59-0.82). Both ACEIs and ARBs were not associated with a decrease in the risk for stroke in patients with DM. Meta-regression analysis showed that the ACEI treatment effect on all-cause mortality and CV death did not vary significantly with the starting baseline blood pressure and proteinuria of the trial participants and the type of ACEI and DM. CONCLUSIONS AND RELEVANCE Angiotensin-converting enzyme inhibitors reduced all-cause mortality, CV mortality, and major CV events in patients with DM, whereas ARBs had no benefits on these outcomes. Thus, ACEIs should be considered as first-line therapy to limit excess mortality and morbidity in this population.

Protective Effect of Levamlodipine on Renal Function in Patients with Essential Hypertension: A Meta-analysis

Effects of Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease: A Systemic Review and Meta-Analysis

Aliskiren Therapy in Hypertension and Cardiovascular Disease: a Systematic Review and a Meta-Analysis

Meta-analysis of Effectiveness and Safety of Levoamlodipine and Amlodipine for Essential Hypertension

The safety and efficiency of low-dose mineralocorticoid receptor antagonists in dialysis patients: a meta-analysis

The Safety And Efficacy Of Low-Dose Mineralocorticoid Receptor Antagonists In Dialysis Patients A Meta-Analysis

Effect of telmisartan on microalbuminuria in patients with hypertension

Effect and safety of levoamlodipine maleate tablets on patients with mild-to-moderate hypertension

Clinical Effect Of Mineralocorticoid Receptor Antagonist Combined With Angiotensin Receptor Blocker Or Angiotensin Converting Enzyme Inhibitor In Treating Diabetic Nephropathy: A Systematic Review And Meta-Analysis

Influence of valsartan on Microalbuminuria of Essential Hypertensive Patients

Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease

Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.

Renoprotective Effects of Renin-Angiotensin System Inhibitor Combined with Calcium Channel Blocker or Diuretic in Hypertensive Patients: A PRISMA-compliant Meta-Analysis.

Meta-analysis of Effectiveness of Amlodipine Combined with Adrenergic Inhibitors for Essential Hypertension

Renal protection effects of benidipine in patients with hypertension: meta-analysis

Effect of levamlodipine besylate on vascular function in patients with mild-to-moderate hypertension

Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis.

Comparative Efficacy And Safety Of Antihypertensive Agents For Adult Diabetic Patients With Microalbuminuric Kidney Disease: A Network Meta-Analysis

Combinative treatment effects of benazepril and levamlodipine against microdose proteinuria in patients with essential hypertension and type 2 diabetes mellitus

Efficacy and safety of amlodipine plus captopril for the treatment of essential hypertension:A Meta-analysis

Effect and safety of telmisartan and amlodipine in treatment of hypertension complicated with diabetes：a Meta-analysis